chartexchange

IBRX270115C00009000
IBRX Jan 15 2027 9.00 Call
optionOPRA

EODOct 16, 2026
1.87USD-25.200%(-0.63)64Vol6,730OI
Loading…
Underlying
Underlying Price
$8.48
Type
Call
Strike
9
Expiration
Jan 15, 2027
DTE
87d
Moneyness
OTM
Intrinsic
$0.00
IBRX 9 Call Across Expirations
ExpirationDTELastChangeVolOpen Int
Oct 23, 20263d$0.50-60.00%168243
Oct 30, 202610d$0.74-50.67%4371,164
Nov 6, 202617d$1.10-26.17%1864
Nov 13, 202624d$1.19-38.02%512
Nov 20, 202631d$1.10-38.89%405,958
Nov 27, 202638d$1.86+0.00%1010
Dec 18, 202659d$2.00+0.00%400400
Jan 15, 202787d$1.87-25.20%646,730
Mar 19, 2027150d$2.30-24.09%73428
Apr 16, 2027178d$3.40-12.82%142
May 21, 2027213d$4.00+65.29%114
IBRX Nearby Strikes · Jan 15, 2027
StrikeLastChangeVolOpen IntMoneyness
3.5 C$6.54-7.23%44,158ITM
4 C$5.70-6.10%15,546ITM
4.5 C$6.02+28.36%252,469ITM
5 C$4.40-16.98%4126,601ITM
5.5 C$4.50-12.62%17,668ITM
7.5 C$2.65-11.67%31521,039ITM
9 C$1.87-25.20%646,730OTM
10 C$1.55-26.19%2,28072,137OTM
11 C$1.15-32.35%39216,123OTM
12 C$1.00-31.03%71710,602OTM
13 C$0.89-33.58%66898OTM
14 C$1.00-16.67%103,110OTM
15 C$0.62-26.19%59813,429OTM
IBRX Profile

immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.